Pharma contract manufacturing and research firms witnessed a disappointing third quarter, raising concerns among investors for a sector that was considered one of the best bets during the pandemic. As a result, most stocks in the category are trading close to their 52-week lows and analysts do not see an immediate growth trigger for the sector. B&K Securities in a report said: Specialty CDMO is on track to commercialise a fourth molecule in FY24. It derives a large portion of its revenues from the provision of contract research organisation services. Investment in the sterile injectables facility. Manchanda said that for a CDMO business operating from India, it is possible to earn Ebitda margins to the extent of 50–60%. Source - https://www.bqprime.com/business/contract-drugmakers-grapple-with-reality-check-after-covid-exuberance
17 Apr 12:27 PM
17 Apr 12:27 PM
Diesel Price had declined across the country after over a month on Wednesday. However, the petrol prices have remained unchanged for Read more
17 Apr 12:27 PM
Diesel Price had declined across the country after over a month on Wednesday. However, the petrol prices have remained unchanged for Read more
reports
We will suggest you loops to join based on your interests.
of {News }
Insufficient balance. Please click here to top up wallet.
Current balance: $ 0
Don't have an account? Register
Mobile not accessible? Login with email
Email not accessible? Login with SMS
Already have an account? Login
Complete advanced KYC to access core functionalities of loop